Gilead and LG Life Sciences Announce Global License Agreement

November 8, 2007

Gilead Sciences, Inc. and LG Life Sciences, Ltd. announced that the companies have entered into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.
The Healthcare Sales & Marketing Network